Avadel Pharmaceuticals plc (AVDL)
USD 7.61
(6.73%)
USD 7.61
(6.73%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 164.96 Million USD | 71.4% |
| 2022 | 95.21 Million USD | 11.23% |
| 2021 | 85.59 Million USD | 60.74% |
| 2020 | 53.25 Million USD | -16.68% |
| 2019 | 63.91 Million USD | -56.31% |
| 2018 | 146.3 Million USD | 51.24% |
| 2017 | 96.73 Million USD | 4.38% |
| 2016 | 92.67 Million USD | 54.76% |
| 2015 | 59.88 Million USD | 33.83% |
| 2014 | 44.74 Million USD | 11.88% |
| 2013 | 39.99 Million USD | -0.69% |
| 2012 | 40.26 Million USD | 12.17% |
| 2011 | 35.89 Million USD | -10.3% |
| 2010 | 40.02 Million USD | -8.53% |
| 2009 | 43.75 Million USD | -11.0% |
| 2008 | 49.15 Million USD | -18.32% |
| 2007 | 60.18 Million USD | 8.23% |
| 2006 | 55.6 Million USD | -10.08% |
| 2005 | 61.84 Million USD | 43.91% |
| 2004 | 42.97 Million USD | 64.08% |
| 2003 | 26.19 Million USD | 61.11% |
| 2002 | 16.25 Million USD | 15.49% |
| 2001 | 14.07 Million USD | -44.27% |
| 2000 | 25.25 Million USD | 58.33% |
| 1999 | 15.95 Million USD | 4.4% |
| 1998 | 15.28 Million USD | 9.14% |
| 1997 | 14 Million USD | 3.7% |
| 1996 | 13.5 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 51.69 Million USD | 18.39% |
| 2024 Q2 | 51.45 Million USD | -0.45% |
| 2023 Q2 | 51 Million USD | 80.23% |
| 2023 Q1 | 28.29 Million USD | 21.89% |
| 2023 FY | 163.2 Million USD | 71.4% |
| 2023 Q3 | 42 Million USD | -17.63% |
| 2023 Q4 | 43.66 Million USD | 3.94% |
| 2022 Q4 | 23.21 Million USD | 36.33% |
| 2022 Q2 | 26.34 Million USD | -7.97% |
| 2022 FY | 95.21 Million USD | 11.23% |
| 2022 Q3 | 17.02 Million USD | -35.36% |
| 2022 Q1 | 28.62 Million USD | 23.73% |
| 2021 FY | 85.59 Million USD | 60.74% |
| 2021 Q1 | 14.86 Million USD | 4.24% |
| 2021 Q2 | 21.93 Million USD | 47.58% |
| 2021 Q4 | 23.13 Million USD | -9.85% |
| 2021 Q3 | 25.66 Million USD | 16.99% |
| 2020 Q2 | 11.35 Million USD | -16.79% |
| 2020 Q1 | 13.64 Million USD | -12.67% |
| 2020 Q3 | 13.99 Million USD | 23.22% |
| 2020 Q4 | 14.26 Million USD | 1.92% |
| 2020 FY | 53.25 Million USD | -16.68% |
| 2019 Q3 | 13.06 Million USD | -24.31% |
| 2019 Q4 | 15.62 Million USD | 19.65% |
| 2019 Q2 | 17.25 Million USD | -4.02% |
| 2019 Q1 | 17.97 Million USD | -41.84% |
| 2019 FY | 63.91 Million USD | -56.31% |
| 2018 Q1 | 36.2 Million USD | -2.54% |
| 2018 FY | 146.3 Million USD | 51.24% |
| 2018 Q2 | 41.34 Million USD | 14.19% |
| 2018 Q3 | 37.85 Million USD | -8.44% |
| 2018 Q4 | 30.9 Million USD | -18.34% |
| 2017 Q2 | 19.78 Million USD | 1.04% |
| 2017 Q1 | 19.58 Million USD | -27.83% |
| 2017 FY | 96.73 Million USD | 4.38% |
| 2017 Q4 | 37.15 Million USD | 83.71% |
| 2017 Q3 | 20.22 Million USD | 2.21% |
| 2016 Q3 | 24.58 Million USD | 8.8% |
| 2016 Q2 | 22.59 Million USD | 23.05% |
| 2016 Q1 | 18.36 Million USD | 21.53% |
| 2016 FY | 92.67 Million USD | 54.76% |
| 2016 Q4 | 27.13 Million USD | 10.37% |
| 2015 Q3 | 14.93 Million USD | -7.93% |
| 2015 Q4 | 15.11 Million USD | 1.21% |
| 2015 Q1 | 13.62 Million USD | 337.64% |
| 2015 Q2 | 16.21 Million USD | 18.99% |
| 2015 FY | 59.88 Million USD | 33.83% |
| 2014 Q1 | 13.58 Million USD | 45.2% |
| 2014 FY | 44.74 Million USD | 11.88% |
| 2014 Q4 | 3.11 Million USD | -77.87% |
| 2014 Q2 | 13.97 Million USD | 2.86% |
| 2014 Q3 | 14.07 Million USD | 0.68% |
| 2013 Q1 | 11.02 Million USD | 20.94% |
| 2013 FY | 39.99 Million USD | -0.69% |
| 2013 Q3 | 9.6 Million USD | -4.05% |
| 2013 Q2 | 10.01 Million USD | -9.17% |
| 2013 Q4 | 9.35 Million USD | -2.58% |
| 2012 FY | 40.26 Million USD | 12.17% |
| 2012 Q4 | 9.11 Million USD | 1.97% |
| 2012 Q1 | 6.08 Million USD | -32.92% |
| 2012 Q2 | 4.27 Million USD | -29.83% |
| 2012 Q3 | 8.93 Million USD | 109.18% |
| 2011 Q3 | 8.06 Million USD | -4.83% |
| 2011 FY | 35.89 Million USD | -10.3% |
| 2011 Q4 | 9.07 Million USD | 12.54% |
| 2011 Q1 | 10.28 Million USD | 7.83% |
| 2011 Q2 | 8.47 Million USD | -17.6% |
| 2010 Q2 | 10.65 Million USD | -22.11% |
| 2010 FY | 40.02 Million USD | -8.53% |
| 2010 Q4 | 9.53 Million USD | -27.35% |
| 2010 Q1 | 13.68 Million USD | 69.05% |
| 2010 Q3 | 13.12 Million USD | 23.17% |
| 2009 Q3 | 12.44 Million USD | -3.43% |
| 2009 FY | 43.75 Million USD | -11.0% |
| 2009 Q4 | 8.09 Million USD | -34.95% |
| 2009 Q1 | 10.33 Million USD | -14.07% |
| 2009 Q2 | 12.88 Million USD | 24.72% |
| 2008 Q1 | 13.35 Million USD | -2.76% |
| 2008 Q4 | 12.02 Million USD | 7.95% |
| 2008 Q3 | 11.13 Million USD | -11.92% |
| 2008 FY | 49.15 Million USD | -18.32% |
| 2008 Q2 | 12.64 Million USD | -5.28% |
| 2007 Q4 | 13.73 Million USD | -2.15% |
| 2007 Q3 | 14.03 Million USD | -20.98% |
| 2007 Q2 | 17.75 Million USD | 21.09% |
| 2007 Q1 | 14.66 Million USD | -1.54% |
| 2007 FY | 60.18 Million USD | 8.23% |
| 2006 FY | 55.6 Million USD | -10.08% |
| 2006 Q4 | 14.89 Million USD | 4.83% |
| 2006 Q3 | 14.2 Million USD | 8.32% |
| 2006 Q2 | 13.11 Million USD | 0.15% |
| 2006 Q1 | 13.09 Million USD | -22.17% |
| 2005 Q2 | 15.15 Million USD | -1.26% |
| 2005 Q3 | 14.51 Million USD | -4.25% |
| 2005 FY | 61.84 Million USD | 43.91% |
| 2005 Q1 | 15.34 Million USD | -33.39% |
| 2005 Q4 | 16.82 Million USD | 15.96% |
| 2004 Q1 | 9.73 Million USD | 10.04% |
| 2004 Q2 | 10.19 Million USD | 4.79% |
| 2004 Q4 | 23.04 Million USD | 125.96% |
| 2004 Q3 | 10.19 Million USD | 0.0% |
| 2004 FY | 42.97 Million USD | 64.08% |
| 2003 Q2 | 6.02 Million USD | 24.03% |
| 2003 Q1 | 4.85 Million USD | -4.47% |
| 2003 Q4 | 8.84 Million USD | 36.78% |
| 2003 FY | 26.19 Million USD | 61.11% |
| 2003 Q3 | 6.46 Million USD | 7.36% |
| 2002 FY | 16.25 Million USD | 15.49% |
| 2002 Q1 | - USD | 100.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | 3.67 Million USD | 0.0% |
| 2002 Q4 | 5.08 Million USD | 38.24% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q4 | -16.24 Million USD | 0.0% |
| 2001 FY | 14.07 Million USD | -44.27% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q1 | - USD | 100.0% |
| 2000 Q4 | -27 Million USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 100.0% |
| 2000 FY | 25.25 Million USD | 58.33% |
| 2000 Q3 | - USD | 0.0% |
| 1999 FY | 15.95 Million USD | 4.4% |
| 1999 Q4 | -18.04 Million USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 100.0% |
| 1998 Q2 | - USD | -100.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | 15.28 Million USD | 9.14% |
| 1998 Q4 | -18.81 Million USD | 0.0% |
| 1998 Q1 | 3.9 Million USD | 122.81% |
| 1997 Q4 | -17.1 Million USD | 0.0% |
| 1997 FY | 14 Million USD | 3.7% |
| 1997 Q1 | - USD | 100.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1996 Q2 | - USD | -100.0% |
| 1996 Q1 | 3.3 Million USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | -13.9 Million USD | 0.0% |
| 1996 FY | 13.5 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -1898.892% |
| Alpha Teknova, Inc. | 45.85 Million USD | -259.724% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 15.826% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -267.784% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -3.617% |
| Cosmos Health Inc. | 26.18 Million USD | -530.103% |
| Journey Medical Corporation | 54.59 Million USD | -202.169% |
| Embecta Corp. | 528.4 Million USD | 68.78% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 39.328% |
| Dynavax Technologies Corporation | 219.14 Million USD | 24.723% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 72.04% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 49.455% |
| PainReform Ltd. | 9.58 Million USD | -1621.265% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1156.935% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1156.935% |
| SCYNEXIS, Inc. | 51.84 Million USD | -218.172% |
| Safety Shot Inc | 12.1 Million USD | -1262.264% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -5274.907% |
| Procaps Group, S.A. | 199.47 Million USD | 17.301% |
| Theratechnologies Inc. | 72.75 Million USD | -126.739% |
| Harrow Health, Inc. | 89.97 Million USD | -83.351% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -1646.411% |
| Biofrontera Inc. | 39.95 Million USD | -312.838% |
| DURECT Corporation | 43.71 Million USD | -277.367% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 68.816% |
| Cronos Group Inc. | 96.7 Million USD | -70.58% |
| OptiNose, Inc. | 85.1 Million USD | -93.845% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 28.932% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -321.337% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 1825.405% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 47.485% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -1595.291% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -283.28% |
| Radius Health, Inc. | 265.92 Million USD | 37.966% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1091.787% |
| ProPhase Labs, Inc. | 37.85 Million USD | -335.818% |
| Phibro Animal Health Corporation | 260.29 Million USD | 36.624% |
| Procaps Group S.A. | 187.24 Million USD | 11.898% |
| Alvotech | 285.43 Million USD | 42.206% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -1579.043% |
| Viatris Inc. | 5.96 Billion USD | 97.235% |
| Rockwell Medical, Inc. | 15.37 Million USD | -973.019% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -175.678% |
| SIGA Technologies, Inc. | 22.04 Million USD | -648.382% |
| Tilray Brands, Inc. | 251.35 Million USD | 34.37% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -236.404% |
| Shineco, Inc. | 17.94 Million USD | -819.131% |
| PetIQ, Inc. | 192.72 Million USD | 14.403% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -4033.307% |
| Incannex Healthcare Limited | 30.05 Million USD | -448.917% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 89.667% |
| Alimera Sciences, Inc. | 62.64 Million USD | -163.351% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -21535.112% |
| Assertio Holdings, Inc. | 368.58 Million USD | 55.243% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -2702.889% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -826.331% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -679.281% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -683.981% |
| Hempacco Co., Inc. | 7.59 Million USD | -2071.62% |
| Talphera, Inc. | 11.99 Million USD | -1275.404% |
| Alvotech | 285.43 Million USD | 42.206% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -17.235% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 52.17% |
| Currenc Group, Inc. | 24 Million USD | -587.299% |
| Kamada Ltd. | 45.42 Million USD | -263.153% |
| Indivior PLC | 911 Million USD | 81.892% |
| Evoke Pharma, Inc. | 12.4 Million USD | -1229.337% |
| Flora Growth Corp. | 10.57 Million USD | -1459.372% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -683.981% |
| Evolus, Inc. | 189.75 Million USD | 13.066% |
| HUTCHMED (China) Limited | 436.23 Million USD | 62.184% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -7.028% |
| Akanda Corp. | 3.48 Million USD | -4635.629% |